Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NJH395 in non-breast HER2+ advanced malignancies
NCT03696771Phase 1Completed
- Sponsor
- Novartis
- Start
- Dec 2018
- Primary completion
- Oct 2020
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of NJH395 in HER2-positive solid tumor (HER2+), sponsored by Novartis. Primary endpoints: Incidence and severity of dose limiting toxicities at 21 days and Number of participants with Adverse Events at 2.5 years. Started Dec 2018; status: completed.
02
Drugs
NJH395
03
Conditions
HER2-positive solid tumor (HER2+)
Beyond the preview
Go deeper on NCT03696771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03696771.